ArticleInfectious diseases and therapy2023

Safety and Immunogenicity of Homologous Recombinant Adenovirus Type 5-Vectored COVID-19 Vaccine Booster Dose in Healthy Adults Aged 18-60 Years: a Single-Center, Open-Label Trial.

Siyue Jia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.